Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC)::An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial

Autor: Marianne Kiszka-Kanowitz, Klaus Theede, Sandra Bohn Thomsen, Jacob Tveiten Bjerrum, Jørn Brynskov, Ida Benedikte Gottschalck, Elena Akimenko, Karen Lisa Hilsted, Anders Neumann, Signe Wildt, Lone Larsen, Jens Kristian Munk, Per Holger Ibsen, Huma Gul Rehana Janjua, Lise Lotte Gluud, Anette Mertz-Nielsen

Publikováno v: Kiszka-Kanowitz, M, Theede, K, Thomsen, S B, Bjerrum, J T, Brynskov, J, Gottschalck, I B, Akimenko, E, Hilsted, K L, Neumann, A, Wildt, S, Larsen, L, Munk, J K, Ibsen, P H, Janjua, H G R, Gluud, L L & Nielsen, A M 2022, ' Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial ', EClinicalMedicine, vol. 45, 101332 . https://doi.org/10.1016/j.eclinm.2022.101332
Kiszka-Kanowitz, M, Theede, K, Thomsen, S B, Bjerrum, J T, Brynskov, J, Gottschalck, I B, Akimenko, E, Hilsted, K L, Neumann, A, Wildt, S, Larsen, L, Munk, J K, Ibsen, P H, Janjua, H G R, Gluud, L L & Mertz-Nielsen, A 2022, ' Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC) : An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial ', EClinicalMedicine, vol. 45, 101332 . https://doi.org/10.1016/j.eclinm.2022.101332

Background: Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA). We pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b9f76555ea753d957889bc724b3741a
https://vbn.aau.dk/da/publications/61c3cd43-3e43-4958-a918-97d2a63c25e7

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease

Autor: Ole Østergaard Thomsen, Hans Christian Slotved, Sofie Ingdam Halkjær, Bjørn Kantsø, Ida Benedikte Gottschalck, Andreas Petersen, Helene Ingels, Charlotte Sværke Jørgensen, Karen A. Krogfelt, Erika Belard

Publikováno v: Vaccine. 33:5464-5469

Background Patients with Crohn's disease (CD) have a higher risk of infectious diseases including pneumococcal infections, and the risk increases with immunotherapy. The primary endpoint of this study was to investigate the specific antibody response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296433f8c8df7d757a75f6c5b2c4fd36
https://doi.org/10.1016/j.vaccine.2015.08.011